Pharmacy Benefit Manager Accountability Study Act of 2021
USA117th CongressHR-1829| House
| Updated: 3/12/2021
Diana Harshbarger
Republican Representative
Tennessee
Cosponsors (29)
Matthew M. Rosendale (Republican)Steve Chabot (Republican)Yvette Herrell (Republican)Gregory F. Murphy (Republican)Jefferson Van Drew (Republican)Victoria Spartz (Republican)Glenn Thompson (Republican)Mariannette Miller-Meeks (Republican)Steve Cohen (Democratic)Jerry L. Carl (Republican)Earl L. "Buddy" Carter (Republican)Scott Perry (Republican)H. Morgan Griffith (Republican)Rodney Davis (Republican)Mike Kelly (Republican)Nancy Mace (Republican)Dean Phillips (Democratic)Kat Cammack (Republican)Glenn Grothman (Republican)Cynthia Axne (Democratic)Mary E. Miller (Republican)Peter Welch (Democratic)Bill Posey (Republican)Burgess Owens (Republican)Ben Cline (Republican)Ralph Norman (Republican)Tracey Mann (Republican)Fred Keller (Republican)Michael Guest (Republican)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Pharmacy Benefit Manager Accountability Study Act of 2021 This bill requires the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Congressional oversightDrug therapyGovernment employee pay, benefits, personnel managementGovernment studies and investigationsHealth care costs and insuranceInflation and pricesMedicaidMedicarePrescription drugs
Pharmacy Benefit Manager Accountability Study Act of 2021
USA117th CongressHR-1829| House
| Updated: 3/12/2021
Pharmacy Benefit Manager Accountability Study Act of 2021 This bill requires the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Diana Harshbarger
Republican Representative
Tennessee
Cosponsors (29)
Matthew M. Rosendale (Republican)Steve Chabot (Republican)Yvette Herrell (Republican)Gregory F. Murphy (Republican)Jefferson Van Drew (Republican)Victoria Spartz (Republican)Glenn Thompson (Republican)Mariannette Miller-Meeks (Republican)Steve Cohen (Democratic)Jerry L. Carl (Republican)Earl L. "Buddy" Carter (Republican)Scott Perry (Republican)H. Morgan Griffith (Republican)Rodney Davis (Republican)Mike Kelly (Republican)Nancy Mace (Republican)Dean Phillips (Democratic)Kat Cammack (Republican)Glenn Grothman (Republican)Cynthia Axne (Democratic)Mary E. Miller (Republican)Peter Welch (Democratic)Bill Posey (Republican)Burgess Owens (Republican)Ben Cline (Republican)Ralph Norman (Republican)Tracey Mann (Republican)Fred Keller (Republican)Michael Guest (Republican)
Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Congressional oversightDrug therapyGovernment employee pay, benefits, personnel managementGovernment studies and investigationsHealth care costs and insuranceInflation and pricesMedicaidMedicarePrescription drugs